Use of a composition comprising microorganisms to increase the intestinal production of butyric acid, folic acid or niacin and/or decrease the intestinal production of succinic acid
Inventors
Guglielmetti, Simone Domenico • ROSSI, Ruggero • FIORE, Walter • BIFFI, Andrea
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11839634-B2
Publication Date
2023-12-12
Expiration Date
Abstract
The present invention relates to the use of a composition comprising bacteria to increase the intestinal production of butyric acid, folic acid or niacin and/or to decrease the intestinal production of succinic acid. Moreover, the present invention relates to the use of said composition for the treatment and/or prevention of an intestinal butyrate- and/or succinate-dependent pathological condition. In particular, for the treatment and/or the prevention of intestinal inflammation, diarrhoea, ulcerative colitis or intestinal colopathies.
Core Innovation
The invention relates to a method for preventing an intestinal butyrate and succinate-dependent pathological condition in a healthy subject by orally administering a composition comprising a bacterium Lactobacillus paracasei DG with Accession Number CNCM 1-1572. The method is directed to increasing intestinal production of butyric acid and decreasing intestinal production of succinic acid (succinate). The composition is used to prevent intestinal pathological outcomes in the healthy subject that depend on butyrate and succinate.
The invention links the method to modulation of intestinal microbiota, in particular an increase of Coprococcus and a decrease of Blautia. Coprococcus is described as a major butyrate producer that can use succinate, while Blautia is described as involving acetate/succinate end-products. The described microbiota shifts are associated with increased faecal butyric acid and reduced succinate.
The invention further relates to intestinal production of folic acid and/or niacin, directly or indirectly, in connection with the described microbiota modulation. In silico metagenomic reconstruction is described as suggesting increased folic acid biosynthesis and increased nicotinic acid metabolism. The intervention is used in the context of randomized, double-blind, placebo-controlled crossover dietary intervention in healthy individuals.
Claims Coverage
The partial content provides one independent claim. The independent claim specifies prevention in a healthy subject by oral administration of Lactobacillus paracasei DG (CNCM 1-1572) and defines the targeted intestinal pathological condition as diarrhoea and at least one of gastric atrophy, intestinal stenosis, intestinal obstructions, and diabetic neuropathy.
Prevention of intestinal butyrate- and succinate-dependent pathological condition in a healthy subject
A method for preventing an intestinal butyrate and succinate-dependent pathological condition in a healthy subject by orally administering a composition comprising Lactobacillus paracasei DG, Accession Number CNCM 1-1572, to prevent the intestinal butyrate and succinate-dependent pathological condition.
Oral administration of Lactobacillus paracasei DG (CNCM 1-1572) composition
Orally administering a composition comprising Lactobacillus paracasei DG, Accession Number CNCM 1-1572, to prevent the intestinal butyrate and succinate-dependent pathological condition in the healthy subject.
Targeting diarrhoea and specified colopathy manifestations
Wherein the intestinal pathological condition is diarrhoea and at least one of gastric atrophy, intestinal stenosis, intestinal obstructions and diabetic neuropathy.
Across the provided independent claim, the inventive coverage is directed to orally preventing an intestinal butyrate- and succinate-dependent pathological condition in healthy subjects by administering Lactobacillus paracasei DG (CNCM 1-1572) and targeting diarrhoea together with one or more specified intestinal/neuropathic manifestations.
Stated Advantages
Documented Applications
No documented applications found
Interested in licensing this patent?